Nativis Voyager Device: Publication of Study in Patients with Recurrent Glioblastoma Announced by Nativis

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

December 19, 2018

Nativis, Inc. today announced the publication of an early feasibility study in CNS Oncology suggesting that the Nativis Voyager device is safe for treatment of rGBM. (Nativis is a clinical-stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases).

The publication of the study, An Early Feasibility Study of the Nativis Voyager® Device in Patients with Recurrent Glioblastoma: First Cohort in the US, may be viewed on the Nativis web site.

“We are excited to have this publication accepted by CNS Oncology in conjunction with our internationally recognized clinical trial partners, led by Charles Cobbs, MD and Santosh Kesari, MD Ph.D.,” stated Chris Rivera, Nativis Chief Executive Officer. “The data in this early feasibility study not only suggest that the Nativis Voyager device is safe for the treatment of rGBM, but also that further studies to explore clinical utility are warranted.”

The Nativis Voyager produces ultra-low radiofrequency energy (ulRFE®) intended to induce a biologic response in solid tumors, such as rGBM. The ulRFE cognate is created by measuring and recording the oscillating magnetic field produced by molecules in solution. The recorded cognate is then used to reproduce the recorded magnetic field using an electromagnetic coil worn externally on the head by the patient.

“Nativis is grateful to our clinical partners, patients, and their families in this effort to develop an effective treatment for one of the most difficult diseases to treat known to medical science.” Rivera went on to state, “Without the efforts of our dedicated and extraordinary clinical partners, our patients and their families would have fewer hopes to address the devastating effects of rGBM.”

Rivera concluded, “We are looking forward to obtaining data from this ongoing clinical study for the treatment of rGBM, with the expectation of producing safety and clinical utility results that are encouraging for our patients and their families.”

spot_img

DON'T MISS

Related Articles